8-K: Xencor Updates on XmAb942 and XmAb412 Data

Xencor presented final Phase 1 data for XmAb942 and preclinical data for XmAb412, highlighting potential best-in-class profiles for inflammatory bowel disease treatments.

Summary

• Xencor presented final results from the Phase 1 study of XmAb942, an anti-TL1A antibody, and preclinical characterization of XmAb412, a bispecific antibody targeting TL1A and IL23p19.
• XmAb942 demonstrated a favorable safety and tolerability profile in healthy participants, with an estimated terminal half-life of 74.1 days supporting a 12-week maintenance dosing interval.
• XmAb412, utilizing the new XenLock format, showed potent inhibition of both TL1A and IL23 inflammatory pathways and is predicted to have a human half-life of 60-70 days.
• The company is advancing the global Phase 2b XENITH-UC study for XmAb942 in ulcerative colitis, with enrollment on track and a blinded interim analysis expected by year-end 2026.
• A first-in-human study for XmAb412 in healthy participants is slated to begin in the third quarter of 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive update, with strong preclinical and Phase 1 data supporting the advancement of two key pipeline candidates, XmAb942 and XmAb412, in the promising TL1A space.

Positives

• XmAb942 is well-tolerated in healthy participants with no serious or severe treatment-emergent adverse events (TEAEs).
• XmAb942 exhibits an extended serum exposure with an estimated terminal half-life of 74.1 days, supporting a convenient 12-week dosing interval for maintenance therapy.
• XmAb942 demonstrated dose-dependent and durable increases in target engagement (complexed sTL1A) and rapid, sustained reduction of free sTL1A.
• XmAb942 has a favorable immunogenicity profile with a low rate of neutralizing antibodies (2% at the XENITH-UC target dose regimen).
• XmAb412 demonstrates potent inhibition of both TL1A and IL23 inflammatory pathways, with IC50 values comparable or superior to existing therapies.
• XmAb412 is predicted to have a human half-life of 60-70 days, supporting convenient subcutaneous dosing.
• Xencor's TL1A franchise is positioned in a large and growing market for biologic therapies to treat IBD, with anti-TL1A expected to be a cornerstone of advanced therapy.
• Enrollment in the XENITH-UC Phase 2b study for XmAb942 is on track, indicating strong investigator enthusiasm.

Negatives

• Headache was the most common TEAE in the XmAb942 Phase 1 study, occurring in 33% of participants receiving XmAb942 versus 38% receiving placebo.
• Across all XmAb942 doses tested in Phase 1, the incidence of anti-drug antibodies (ADA) was 57%, although no impact on safety or tolerability was observed.
• The XENITH-UC study has an asymmetric randomization ratio, meaning a portion of participants will receive placebo during the induction period.

Risks

• Potential delays in development timelines or negative preclinical or clinical trial results are inherent risks.
• Reliance on third parties for development efforts could impact progress.
• Changes in the competitive landscape, including changes in the standard of care for IBD treatment, pose a risk.
• The success of XmAb942 and XmAb412 is subject to the outcomes of ongoing and future clinical trials, including the XENITH-UC Phase 2b study.
• The development of XmAb412 involves novel XenLock technology, which carries inherent risks associated with new platform development.

Future Outlook

Xencor anticipates key clinical readouts in 2026 and further data advancements in 2027. The company expects to initiate the Phase 1 first-in-human study of XmAb412 in Q3 2026, provide an update on enrollment and a blinded interim analysis of the XENITH-UC study by YE26, and report 12-week induction primary endpoint results for XENITH-UC in 1H27, followed by interim results of the XmAb412 Phase 1 study in 2H27.

Management Comments

• "The Phase 1 results continue to reinforce XmAb942s best-in-class drug exposure and convenient maintenance period dosing schedule - a single subcutaneous injection every 12 weeks - which could be a potential best-in-market advanced treatment option for patients with ulcerative colitis."
• "Consequently, high investigator enthusiasm is driving strong enrollment into our global Phase 2b study of XmAb942 for the treatment of moderately to severely active UC."
• "In addition, we have designed modular XenLock Fab domains to rapidly build native-like, 1+1 format multi-specific antibodies with low- to sub-picomolar affinities, high stability and scalable, high-yield manufacturing."
• "These properties are on display with XmAb412, and we believe the planned start of our first-in-human study in the third quarter of 2026 will mark a new approach to multi-specific biologics that address the very stringent requirements for high potency, long half-life, and low immunogenicity in the treatment of autoimmune and inflammatory disease."

Industry Context

StockSavvy.ai notes that Xencor's focus on TL1A and IL23p19 targets aligns with the growing interest in novel mechanisms for treating inflammatory bowel disease (IBD). The company's strategy to develop potentially best-in-class therapies with convenient dosing schedules addresses a key unmet need in a market with significant sales potential.

Comparison to Industry Standards

• XmAb942's predicted TL1A inhibition (86% >99% in induction, 90% >90% in maintenance) is presented as superior to first-generation anti-TL1A antibodies (31% and 40% in induction, 60% and 68% in maintenance).
• XmAb412's predicted human half-life of 60-70 days is comparable to or longer than other biologics in development for IBD.
• XmAb412's potency against IL23 is stated to be more potent than marketed monospecific IL23 antibodies like Risankizumab, Mirikizumab, and Guselkumab.
• The XmAb942 Phase 1 study reported a lower incidence of neutralizing antibodies (2%) at the target dose regimen compared to other first-generation TL1A antibodies like Duvakitug (57%), Tulisokibart (48%), and Afimkibart (65%).
• Xencor's XenLock platform aims to create 1+1 bispecific antibodies, contrasting with 2+2 formats used by some competitors, potentially avoiding large immune complex formation.

Stakeholder Impact

• Shareholders: Positive data may support future valuation and potential for successful drug development.
• Patients with IBD: Potential for new, more convenient, and effective treatment options with XmAb942 and XmAb412.
• Healthcare Providers: Introduction of novel therapeutic approaches for IBD management.

Next Steps

• Initiate first-in-human study of XmAb412 in healthy participants in Q3 2026.
• Provide update on enrollment and blinded interim analysis of XENITH-UC study by YE26.
• Report 12-week induction primary endpoint results of XENITH-UC study in 1H27.
• Report interim results of the Phase 1 first-in-human study of XmAb412 in 2H27.
• Advance XmAb412 program expansion into new indications in 2028+.

Key Dates

Recommendation

The presented data for XmAb942 and XmAb412 are encouraging, showing potential best-in-class profiles and favorable safety/PK data. However, these are early-stage results (Phase 1 and preclinical). The true value will be determined by the outcomes of the ongoing Phase 2b XENITH-UC study for XmAb942 and subsequent Phase 3 trials. While positive, the data does not yet warrant a strong buy or sell recommendation, making 'hold' appropriate pending further clinical validation.

Keywords

Xencor, XmAb942, XmAb412, TL1A, IL23, IBD, Ulcerative Colitis, Digestive Disease Week